Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HIGHLIGHTS FIRST THREE DRILL HOLES COMPLETED AT RIB EAST DISCOVERY SUCCESSFULLY TARGETED STACKED GRAVITY, EM AND STRUCTURAL ANOMALIES (FIGURE 2), AND INTERSECTED URANIUM MINERALIZATION, AS PART OF THE 2025 ANGILAK EXPLORATION PROGRAM COMPRISING 10,000 M OF DIAMOND DRILLING (FIGURE 1); RESULTS REPRESENT THE SECOND NEW DISCOVERY OF URANIUM MINERALIZATION - BEYOND THE LAC 50 DEPOSIT TREND - DURING THE 2025 ANGILAK EXPLORATION PROGRAM, WITHIN THE ANGIKUNI BASIN ALONG THE 31 KM RIB-NINE IRON TREND; MINERALIZATION AT RIB EAST DISCOVERY IS CURRENTLY DEFINED BY THREE DRILL HOLES, ALL INTERSECTING SHALLOW URANIUM MINERALIZATION (10,000 CPS) OVER A CONTINUOUS 1.0 M WITH MAX RADIOACTIVITY OF 30,730 CPS 1 (FIGURE 3A, B & 6) AND A LOWER GRADE MINERALIZED FRACTURE INTERSECTED BETWEEN 372 M AND 372.6 M. RIBE-DD-003 WAS DRILLED 200 M ALONG STRIKE OF RIBE-DD-002 AND 150 M FURTHER INTO THE HANGING WALL OF AN INTERPRETED NW TRENDING FAULT ZONE.

ATHA DISCOVERS ATHABASCA-STYLE HIGH-GRADE MINERALIZATION AT RIB EAST

WHITE ROCK, BC / ACCESS NEWSWIRE / JULY 14, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA GOLD" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF ITS COMPREHENSIVE TILL SURVEY AT ITS LAIRD LAKE GOLD PROJECT, LOCATED IN ONTARIO'S PROLIFIC RED LAKE GOLD DISTRICT. THE SURVEY, COMPLETED AHEAD OF SCHEDULE, MARKS A SIGNIFICANT MILESTONE IN ADVANCING THE COMPANY'S EXPLORATION STRATEGY ON THIS HIGHLY PROSPECTIVE 4,158-HECTARE PROPERTY, WHICH SPANS OVER 10 KM OF THE BALMER-CONFEDERATION ASSEMBLAGE CONTACT.

ATHENA GOLD COMPLETES TILL SURVEY AT LAIRD LAKE PROJECT IN ONTARIO'S RED LAKE GOLD CAMP

HIGHLIGHTS COMPLETES FIRST TWO DRILL HOLES OF ITS 2025 ANGILAK EXPLORATION PROGRAM COMPRISING ~10,000M OF DIAMOND DRILLING. KU DISCOVERY TARGET: THE MAIDEN DRILL HOLE, KU-DD-001 SUCCESSFULLY TARGETED STACKED GRAVITY AND STRUCTURAL ANOMALIES (FIGURE 2), INTERSECTING SHALLOW HIGH-GRADE URANIUM MINERALIZATION AS WELL AS NUMEROUS ZONES OF LOWER-GRADE MINERALIZATION THROUGHOUT THE HOLE.

ATHA ENERGY DISCOVERS MINERALIZATION WITHIN THE ANGIKUNI BASIN IN FIRST HOLE AT KU TARGET AND DRILLING AT LAC 50 DEPOSIT EXTENDS MINERALIZATION

HIGHLIGHTS THE 2025 ANGILAK EXPLORATION PROGRAM WILL COMPRISE ~10,000 M OF DIAMOND DRILLING WITH TWO OBJECTIVES: LAC 50 DEPOSIT - EXPANSION OF THE FOOTPRINT OF URANIUM MINERALIZATION. STEPPING OUT ALONG STRIKE AND AT DEPTH FROM THE 2024 EXPLORATION TARGET (AS DEFINED BELOW), WHICH REMAINS OPEN AND UNCONSTRAINED.

ATHA COMPLETES GROUND GEOPHYSICS AND COMMENCES 2025 ANGILAK DIAMOND DRILL EXPLORATION PROGRAM

DATA FROM PHASE 1 CLINICAL TRIAL OF ATH-1105 IN HEALTHY VOLUNTEERS SHOWED A FAVORABLE SAFETY AND TOLERABILITY PROFILE; DOSE PROPORTIONAL PHARMACOKINETICS AND CNS PENETRATION SUPPORT CONTINUED CLINICAL DEVELOPMENT

ATHIRA PHARMA TO PRESENT DATA FROM FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF ATH-1105 AT THE 4TH ANNUAL ALS DRUG DEVELOPMENT SUMMIT

COMPLETED HEALTHY VOLUNTEER PHASE 1 CLINICAL STUDY OF ATH-1105 AS A POTENTIAL TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS); FULL HEALTHY VOLUNTEER DATA EXPECTED IN 2H25

ATHIRA PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PIPELINE AND BUSINESS UPDATES

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VACAVILLE, CALIFORNIA / ACCESS NEWSWIRE / APRIL 28, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA GOLD" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THE CLOSING OF A NON-BROKERED PRIVATE PLACEMENT OF FLOW-THROUGH COMMON SHARES (THE "FT SHARES") PREVIOUSLY ANNOUNCED ON APRIL 7, 2025, AS AMENDED APRIL 21, 2025 (THE "FT OFFERING"). THE COMPANY ISSUED AN AGGREGATE OF 15,300,000 FT SHARES AT A PRICE OF CDN $0.05 PER FT SHARE FOR GROSS PROCEEDS OF CDN$765,000, WHICH REPRESENTS AN OVERSUBSCRIPTION OF CDN$265,000 OF THE ORIGINALLY PLANNED FINANCING.

ATHENA GOLD CLOSES OVERSUBSCRIBED FLOW-THROUGH FINANCING

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS NEWSWIRE / APRIL 22, 2025 / ATHA ENERGY CORP. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THAT, FURTHER TO ITS PRESS RELEASES DATED MARCH 31, 2025 AND APRIL 7, 2025, IT HAS COMPLETED A FULLY-SUBSCRIBED PRIVATE PLACEMENT OFFERING OF: (I) 16,766,490 FLOW-THOUGH COMMON SHARES OF THE COMPANY ("FT SHARES") AT A PRICE OF $0.47 PER FT SHARE; AND (II) 3,475,000 FT SHARES THAT MAY BE IMMEDIATELY RESOLD OR DONATED TO REGISTERED CHARITIES ("CHARITY FT SHARES", AND COLLECTIVELY WITH THE FT SHARES, THE "OFFERED SHARES") AT A PRICE OF $0.61 PER CHARITY FT SHARE FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $10,000,000(THE "OFFERING").

ATHA ENERGY ANNOUNCES CLOSING OF FINANCING FOR AGGREGATE GROSS PROCEEDS OF $10,000,000

COMPLETED HEALTHY VOLUNTEER PHASE 1 CLINICAL STUDY OF ATH-1105 AS A POTENTIAL TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)

ATHIRA PHARMA REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PIPELINE AND BUSINESS UPDATES

BOTHELL, WASH., DEC. 06, 2024 (GLOBE NEWSWIRE) -- ATHIRA PHARMA, INC. (NASDAQ: ATHA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING SMALL MOLECULES TO RESTORE NEURONAL HEALTH AND SLOW NEURODEGENERATION, TODAY PRESENTED PRECLINICAL DATA HIGHLIGHTING TARGET ENGAGEMENT AND NEUROPROTECTIVE EFFECTS OF ATH-1105 IN HUMAN MOTOR NEURONS AT THE MOTOR NEURONE DISEASE ASSOCIATION'S 35TH INTERNATIONAL SYMPOSIUM ON ALS/MND, TAKING PLACE DEC. 6-8, 2024, IN MONTREAL, CANADA.

ATHIRA PHARMA PRESENTS PRECLINICAL DATA HIGHLIGHTING NEUROPROTECTIVE EFFECTS OF ATH-1105 IN MODELS OF ALS AT MOTOR NEURONE DISEASE ASSOCIATION'S 35TH INTERNATIONAL SYMPOSIUM ON ALS/MND

Athira Pharma, Inc.

ATHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Athira Pharma, Inc.

ATHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATHA